Cargill Announces Piglet Nutrition Program

Jun 30, 2014

Cargill recently presented a global nutrition program to help advance piglet liveability. The program aims to help pig farmers increase the life expectancy of their young pigs through a feeding regime that focuses on neonatal nutrition.

According to Cargill, early research suggests that its neonatal pig nutrition program can increase pig livability by as much as 6 per cent.

"With average global piglet livability of about 82%, the mortality of young pigs is a critical challenge for producers around the world, even in the most advanced operations," Brooke Humphrey, Cargill Animal Nutrition global swine technology director said in a release. "At Cargill, we have discovered ways to leverage piglet nutrition and feed processing to help increase livability through our advanced formulation system."

The feed program concentrates on improving neonatal pig nutrition by helping piglets gain weight during the first 28 days of life. Research has shown that mortality is the highest from birth until weaning, approximately 18 per cent. With the new feeding program, the average weaning weight has increased from 6.5 kg to 8.0 kg. The program seeks to encourage maximum feed intake, which correlates with weight gain and a greater likelihood of liveability.

Cargill’s neonatal program is available in liquid and dry feeds. The feed options is expected to be rolled out regionally across the United States over the next year.

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.